- Home
- FULC vs XBIT Comparison
FULC vs XBIT Comparison
Compare FULC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- XBIT
- Stock Information
- Founded
- FULC 2015
- XBIT 2005
- Country
- FULC United States
- XBIT United States
- Employees
- FULC N/A
- XBIT N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- FULC Health Care
- XBIT Health Care
- Exchange
- FULC Nasdaq
- XBIT Nasdaq
- Market Cap
- FULC 221.5M
- XBIT 217.5M
- IPO Year
- FULC 2019
- XBIT 2015
- Fundamental
- Price
- FULC $3.64
- XBIT $7.03
- Analyst Decision
- FULC Hold
- XBIT
- Analyst Count
- FULC 10
- XBIT 0
- Target Price
- FULC $7.44
- XBIT N/A
- AVG Volume (30 Days)
- FULC 676.6K
- XBIT 47.8K
- Earning Date
- FULC 11-13-2024
- XBIT 11-22-2024
- Dividend Yield
- FULC N/A
- XBIT N/A
- EPS Growth
- FULC N/A
- XBIT N/A
- EPS
- FULC N/A
- XBIT N/A
- Revenue
- FULC $81,630,000.00
- XBIT N/A
- Revenue This Year
- FULC $2,821.96
- XBIT N/A
- Revenue Next Year
- FULC N/A
- XBIT N/A
- P/E Ratio
- FULC N/A
- XBIT N/A
- Revenue Growth
- FULC 2582.55
- XBIT N/A
- 52 Week Low
- FULC $2.87
- XBIT $3.51
- 52 Week High
- FULC $13.70
- XBIT $9.96
- Technical
- Relative Strength Index (RSI)
- FULC 50.49
- XBIT 48.89
- Support Level
- FULC $3.38
- XBIT $7.11
- Resistance Level
- FULC $3.63
- XBIT $7.74
- Average True Range (ATR)
- FULC 0.16
- XBIT 0.51
- MACD
- FULC 0.12
- XBIT -0.03
- Stochastic Oscillator
- FULC 87.18
- XBIT 30.20
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.